MindMed is building an IP portfolio and undertaking clinical trials of medicines based on psychedelics. MindMed will also grow it’s pipeline through acquisitions, Joint-Ventures, and collaborative development agreements.
The company believes patients deserve better than to linger in symptom management forever. They help patients make breakthroughs that get them out of the symptom management cycle that’s all too commonplace in mental healthcare.
Stock Performance
MindMed News 139 articles
- Definium's Phase 3 Emerge study of DT120 (LSD) meets primary endpoint in major depression
- Definium flags three Phase 3 DT120 readouts coming in 2026
- Company's Nasdaq ticker switches from MNMD to DFTX
- MindMed unveils full rebrand as Definium Therapeutics, spotlighting late-stage LSD pipeline
- MindMed presents at Jefferies Global Healthcare Conference amid MM120 Phase 3 push
- MindMed reports Q3 2025 results with MM120 Phase 3 program on track
- 2025 Q3 Psychedelic Industry Report
- JAMA publishes full Phase 2b results for MindMed's MM120 (LSD) in generalized anxiety disorder
- MindMed reports Q2 2025 results; three MM120 Phase 3 trials on track
- MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)
- MindMed Appoints Matt Wiley as Chief Commercial Officer
- MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates
- MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder
- MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)
- MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)
- MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy
- MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer
- MindMed Reports Third Quarter 2024 Financial Results and Business Updates
- MindMed to Participate in September Investor Conferences
- MindMed Reports Second Quarter 2024 Financial Results and Business Updates
- MindMed Appoints Stephanie Fagan as Chief Corporate Affairs Officer
- MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT)
- MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)
- New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US
- MindMed Reports First Quarter 2024 Financial Results and Business Updates
- MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York
- MindMed to Present at Upcoming May Medical Conferences
- MindMed Shifts Focus to Nasdaq
- MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder
- MindMed Reports 2023 Financial Results and Business Updates
- MindMed Announces Business Update and Anticipated Milestones for 2024
- MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder
- MindMed Secures $50.0 Million Credit Facility with K2 HealthVentures
- MindMed Reports Second Quarter 2023 Financial Results and Business Highlights
- MindMed Announces Exclusive License Agreement With Catalent for Its Patented Zydis® Fast-Dissolve Technology for Use with MM-120
- Cedar Clinical Research, by Numinus, the top enrolling clinical research site for MindMed’s Phase 2B study evaluating MM-120
- MindMed Releases Investor Presentation Highlighting How the Company is Unlocking the Power of Psychedelics for Patients and Shareholders
- MindMed Publishes Report by Leading FDA Experts Validating MindMed’s MM-120 Drug Development Strategy
- MindMed to Present Data on the Preclinical Activity of MM-402 at the American Society of Clinical Psychopharmacology (ASCP) 2023 Annual Meeting
- MindMed Announces Enrollment Milestone in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)
Showing the 40 most recent of 139 articles.